[go: up one dir, main page]

WO2006038007A3 - Inhibitory analogues to block receptors for microbial pathogenic determinants - Google Patents

Inhibitory analogues to block receptors for microbial pathogenic determinants Download PDF

Info

Publication number
WO2006038007A3
WO2006038007A3 PCT/GB2005/003836 GB2005003836W WO2006038007A3 WO 2006038007 A3 WO2006038007 A3 WO 2006038007A3 GB 2005003836 W GB2005003836 W GB 2005003836W WO 2006038007 A3 WO2006038007 A3 WO 2006038007A3
Authority
WO
WIPO (PCT)
Prior art keywords
microbial pathogenic
inhibitory analogues
block receptors
pathogenic determinants
determinants
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2005/003836
Other languages
French (fr)
Other versions
WO2006038007A2 (en
Inventor
Alastair Sutherland
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Glasgow
Glasgow Caledonian University
Original Assignee
University of Glasgow
Glasgow Caledonian University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Glasgow, Glasgow Caledonian University filed Critical University of Glasgow
Publication of WO2006038007A2 publication Critical patent/WO2006038007A2/en
Publication of WO2006038007A3 publication Critical patent/WO2006038007A3/en
Anticipated expiration legal-status Critical
Priority to GB0708711A priority Critical patent/GB2434580A/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to inhibitory analogues of virulence factors that are capable of blocking receptors for microbial pathogenic determinants that contribute to disease symptoms, in order to reduce the presence of said symptoms. In particular, it relates to inhibitors that are able to act against the toxic effects of Clostridium difficile.
PCT/GB2005/003836 2004-10-05 2005-10-05 Inhibitory analogues to block receptors for microbial pathogenic determinants Ceased WO2006038007A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB0708711A GB2434580A (en) 2004-10-05 2007-05-04 Inhibitory analogues to block receptors for microbial pathogenic determinants

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0422003.4A GB0422003D0 (en) 2004-10-05 2004-10-05 Inhibitory analogues to block receptors for microbial pathogenic determinants
GB0422003.4 2004-10-05

Publications (2)

Publication Number Publication Date
WO2006038007A2 WO2006038007A2 (en) 2006-04-13
WO2006038007A3 true WO2006038007A3 (en) 2006-08-17

Family

ID=33428034

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2005/003836 Ceased WO2006038007A2 (en) 2004-10-05 2005-10-05 Inhibitory analogues to block receptors for microbial pathogenic determinants

Country Status (2)

Country Link
GB (2) GB0422003D0 (en)
WO (1) WO2006038007A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998059053A1 (en) * 1997-06-20 1998-12-30 Queen Mary & Westfield College Immonogenic fragments of toxin a of clostridium difficile
WO2000061761A2 (en) * 1999-04-09 2000-10-19 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
US20030129198A1 (en) * 1999-04-09 2003-07-10 Wilkins Tracy D. Methods to produce high levels of C. difficile toxins

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998059053A1 (en) * 1997-06-20 1998-12-30 Queen Mary & Westfield College Immonogenic fragments of toxin a of clostridium difficile
WO2000061761A2 (en) * 1999-04-09 2000-10-19 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
US20030129198A1 (en) * 1999-04-09 2003-07-10 Wilkins Tracy D. Methods to produce high levels of C. difficile toxins

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CASTAGLIUOLO IGNAZIO ET AL: "A receptor decoy inhibits the enterotoxic effects of Clostridium difficile Toxin A in rat ileum", GASTROENTEROLOGY, vol. 111, no. 2, 1996, pages 433 - 438, XP002383253, ISSN: 0016-5085 *
KINK J A ET AL: "ANTIBODIES TO RECOMBINANT CLOSTRIDIUM DIFFICILE TOXINS A AND B ARE EFFECTIVE TREATMENT AND PREVENT RELAPSE OF C. DIFFICILE-ASSOCIATED DISEASE IN A HAMSTER MODEL OF INFECTION", INFECTION AND IMMUNITY, AMERICAN SOCIETY FOR MICROBIOLOGY. WASHINGTON, US, vol. 66, no. 5, 1 May 1998 (1998-05-01), pages 2018 - 2025, XP002912254, ISSN: 0019-9567 *
SAUERBORN MARKUS ET AL: "The C-terminal ligand-binding domain of Clostridium difficile toxin A (TcdA) abrogates TcdA-specific binding to cells and prevents mouse lethality", FEMS MICROBIOLOGY LETTERS, vol. 155, no. 1, 1 October 1997 (1997-10-01), pages 45 - 54, XP002383252, ISSN: 0378-1097 *
WARD STEPHEN J ET AL: "Local and systemic neutralizing antibody responses induced by intranasal immunization with the nontoxic binding domain of toxin A from Clostridium difficile", INFECTION AND IMMUNITY, vol. 67, no. 10, October 1999 (1999-10-01), pages 5124 - 5132, XP002383254, ISSN: 0019-9567 *

Also Published As

Publication number Publication date
WO2006038007A2 (en) 2006-04-13
GB0708711D0 (en) 2007-06-20
GB2434580A (en) 2007-08-01
GB0422003D0 (en) 2004-11-03

Similar Documents

Publication Publication Date Title
WO2009082701A8 (en) Hcv protease inhibitors and uses thereof
WO2008118332A3 (en) Hydrazido-peptides as inhibitors of hcv ns3-protease
NO20083147L (en) Anti-OX40L antibodies and methods for their use
WO2009026334A3 (en) Treatment with kallikrein inhibitors
EP3632444A3 (en) Topical lfa-1 antagonists for use in localized treatment of immune related disorders
WO2007146965A3 (en) Compounds for the treatment of periodontal disease
DK1863812T3 (en) Dipeptidyl peptidase IV inhibitory compounds, methods for preparing the same and pharmaceutical compositions containing the same as active agents
WO2005067893A3 (en) Pharmaceutical compositions comprising midazolam in a high concentration
NO20081160L (en) Benzimidazolthiophene Compounds
WO2009052431A3 (en) Cd19 binding agents and uses thereof
NO20090047L (en) Anti-DLL4 antibodies and methods for their use
WO2009129267A3 (en) Small molecule inhibitors of the pleckstrin homology domain and methods for using same
WO2008131000A3 (en) 7-substituted indole mcl-1 inhibitors
WO2008055068A3 (en) Inhibitors of histone deacetylase
WO2008030367A3 (en) Selective myostatin inhibitors
WO2007106537A3 (en) Aminoquinolones as gsk-3 inhibitors
WO2009008913A3 (en) P1-nonepimerizable ketoamide inhibitors of hcv ns3 protease
WO2010005565A3 (en) Method of treating glycogen storage disease
NO20083593L (en) Anti-EphrinB2 antibodies and methods for their use
WO2007050793A3 (en) Methods and compositions for the treatment of marfan syndrome and associated disorders
EA200970164A1 (en) Caspase Inhibitors Based on Pyridasinone Carcass
WO2006124684A3 (en) Combination therapy comprising a taxane and a thymidylate synthase inhibitor
WO2012021788A3 (en) Dipeptide calpain inhibitors
WO2007056625A3 (en) Thienopyridine b-raf kinase inhibitors
WO2007016338A3 (en) Use of chk2 kinase inhibitors for cancer treatment

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 0708711

Country of ref document: GB

Kind code of ref document: A

Free format text: PCT FILING DATE = 20051005

WWE Wipo information: entry into national phase

Ref document number: 0708711.7

Country of ref document: GB

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 05796765

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 05796765

Country of ref document: EP

Kind code of ref document: A2